Skip to content

COMPREHENSIVE® REVERSE SHOULDER Mini BasePlate

Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02084693
Enrollment
100
Registered
2014-03-12
Start date
2013-12-31
Completion date
2019-06-30
Last updated
2019-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Joint; Destruction, Sacroiliac, Osteomalacia, Osteoporosis, Rotator Cuff Tear Arthropathy

Brief summary

Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.

Detailed description

The primary objective of this prospective clinical data collection is to evaluate survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate. Secondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes including adverse events, scapular notching, and Constant Score. All shoulders on which data will be collected are legally marketed and none of the devices are investigational or experimental. FDA has cleared this device via Premarket Notification 510(k) K080642. This data collection effort will document the clinical outcomes of the Comprehensive® Reverse shoulders. The data gathered will be collated and used to provide feedback to designing engineers, support marketing efforts, and answer potential questions from reimbursement agencies.

Interventions

Comprehensive® Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff.

Sponsors

Zimmer Biomet
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
60 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

Patients / cases to be included in this study shall utilize the following inclusion criteria: 1. Comprehensive Reverse Shoulder Mini Base Plate and Mini Stem in a reverse shoulder configuration. 2. The patient must be anatomically and structurally suited to receive the implants and a functional deltoid muscle is necessary. 3. Grossly deficient rotator cuff with severe arthropathy and/or 1. Previously failed shoulder joint replacement with a grossly deficient rotator cuff. 2. Primary total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency, or 3. Fracture total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency, or 4. Revision total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency.

Exclusion criteria

* The

Design outcomes

Primary

MeasureTime frameDescription
Survivorship1 yearThe primary objective of this prospective clinical data collection is to evaluate survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.

Secondary

MeasureTime frameDescription
Adverse Events (including dislocation)3 yearSecondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes
Constant-Murley Shoulder Score3 yearSecondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes
Radiographic Evaluation (Plain X-ray and CT)3 yearSecondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes
Scapular Notching3 yearSecondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes
Radiographic Evaluation1 yearSecondary objectives include validation of implant sizing and hardware options as well as collection of mid-term clinical outcomes

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026